NCT06186401View on ClinicalTrials.gov

Anti-EGFRvIII synNotch Receptor Induced Anti-EphA2/IL-13Ralpha2 CAR (E-SYNC) T Cells

PHASE1RecruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

April 30, 2024

Primary Completion Date

August 31, 2026

Study Completion Date

August 31, 2026

Conditions
EGFR Gene MutationGlioblastomaMGMT-Unmethylated GlioblastomaRecurrent Glioblastoma
Interventions
BIOLOGICAL

E-SYNC T Cells

Given IV

DRUG

Cyclophosphamide (non-investigational)

Given IV

DRUG

Fludarabine (non-investigational)

Given IV

PROCEDURE

Leukapheresis

Undergo leukapheresis

PROCEDURE

Surgical resection

Undergo surgical resection of tumor tissue

Trial Locations (1)

94143

RECRUITING

University of California, San Francisco, San Francisco

All Listed Sponsors
collaborator

California Institute for Regenerative Medicine (CIRM)

OTHER

collaborator

National Cancer Institute (NCI)

NIH

lead

Hideho Okada, MD, PhD

OTHER